To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function
NCT05404529
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
32
Enrollment
INDUSTRY
Sponsor class
Conditions
Hepatic Impairment
Interventions
DRUG:
Tavapadon
Sponsor
Cerevel Therapeutics, LLC